(g) and (h) Industrial approvals for manufacture of bulk drugs are given only as per basic stages. Manufacture from late stage intermediates is permitted only in a few cases like Rifampicin, Pentazocin, Sulphadiazine, Pindalol, Ethambutol, Chloroquine Phosphate, Thioridazine etc. by giving relaxation to the basic stage, taking into consideration various reasons like technological constraints, economic viability etc.

Production of New Drugs

1604. SHRI H. HANUMANTHAPPA :
SHRI RAJNI RANJAN SAHU :
SHRIMATI SATYA BAHIN :

Will the PRIME MINISTER be pleased to state :

(a) what are the new bulk drugs produced by M/s. Parke Davis, Boots Pharmaceuticals, Roche Products, Hindustan Ciba Geigy, Duphar Interfran, Hoechst and Glaxo after the announcement of Drug Policy, 1986;

(b) what was the production from the date of commencement of production upto 31st October, 1992 year-wise and what is the stage of manufacture of each drug by each company;

(c) whether it is a fact that all these drugs are outside price control;

(d) what was the sales turnover, net fixed assets and profit before tax of each company year-wise after the announcement of Drug Policy, 1986;

(e) whether it is a fact that profits of these companies have gone up but no new investment has been made by these companies; and

(f) if so, what was the profits on sales turnover and on capital employed during these years ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) : (a) and (b) Since the announcement of the Drug Policy, 1986, Industrial Licences have been given to these companies for the manufacture of seven new drugs indicated in Annexure-I., along with the starting stages. [*See* Appendix CLXV, Annexure No. 29] Data in respect of production of Diclofenac Sodium and Ranitidine is available, which is given at Annexure-I.

(c) Of the seven drugs mentioned in Annexure-I, only Diclofenac Sodium and Ranitidine are under price control.

(d) to (f) The sales turnover, profits before tax and profits on sales turnover in respect of these companies, to the extent available, is given at Annexure-II. [*See* Appendix CLXV, Annexure No. 29]. The information on net fixed assets is not available. The profits/profitability of these companies have varied during this period. However these companies have been given approval for investments around Rs. 28.94 crores for the production of new drugs after the announcement of Drug Policy, 1986.

Increase in the Prices of Pyrental Pamoate

1605. SHRI HANUMANTHAPPA :
SHRI RAJNI RAJAN SAHU :
SHRIMATI SATYA BAHIN :

Will the PRIME MINISTER be pleased to state :

(a) whether it is a fact that the prices of Pyrental Pamoate was increased from Rs. 1282/- per Kg to Rs. 1346 - per Kg. based on interim price fixed under DPCO, 1979 for one year, if so, what are the reasons therefor;

(b) whether it is a fact that no cost study has been done hereafter although this drug is available at Rs. 900/- per Kg.

(c) what is the present notified price and when its price was increased and what were the basis on which the price was increased in the absence of cost study by BICP; and

(d) what steps have been taken to reduce the price ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) : (a) to (d) Under DPCO, 1987 BICP studied cost structure of Pyrental Pamoate and submitted its report in October, 1989. The continuation of price of this bulk drug at Rs. 1250 per kg. was notified on the basis of the above BICP report. The

price was increased to Rs. 1282 per kg. due to impact of change in Exchange Rate of Rupee against major foreign currencies, with effect from 30th August, 1991. On 26th Feb., 1992, the price was again revised to Rs. 1346 per kg. on the basis of representation of its sole manufacturer M/s. Pfizer as per the escalation formula inbuilt in the BICP report. No instance has come to the notice of the Government that this bulk drug is available at Rs. 900 per kg.

Over-invoicing of Carbamezapine Drug

1606. SHRIMATI SATYA BAHIN :
SHRI RAJNI RANJAN SAHU:
SHRI H. HANUMANTHAPPA:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 728 given in Rajya Sabha on the 16th July, 1992 and state :

(a) whether it is a fact that the current leader/ceiling price of Carbamezapine Tablets is based on landed cost of import of Carbamezapine of Rs. 4500 per kg.

(b) whether it is a fact that the current landed cost of import is only Rs. 3200/- kg. and when was the ceiling price fixed on the landed cost of import of Rs. 4500 per kg;

(c) whether it is a fact that import of Carbamezapine required for Syrup is being over-invoiced and what are the reasons for giving more than two times C.I.F. for this drug on quality considerations;

(d) whether it is a fact that the source which is supplying Carbamezapine syrup variety, is also supplying tablet variety of carbamezapine at Rs. 2800 per Kg.; and

(e) what are the names of other drugs the import of which is being over-invoiced ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) : (a) and (b) The current ceiling prices of Carbamezapine Tablets fixed on 9-7-1992 are based on landed cost of Rs. 4,364.21 per Kg. arrived at from DGHS weighted average c.i.f. price data for 1990-91, with due adjustments for exchange rates and applicable duties. DGHS weighted average c.i.f. price data for 1991-92 has become just available and the landed cost works out to Rs. 3,007.87 per Kg. and the prices of formulations are under suo-moto revision.

(c) and (d). The supply of Carbamezapine from one source is at higher c.i.f. price. This higher price was adopted as a special case on the quality and its suitability considerations for the manufacture of syrup only, keeping in view the fact that this formulation is meant for paediatric use and manufactured by only one company. This higher price though claimed for tablets also, was however, not admitted.

(e) to the extent information is available there is no specific evidence of over-invoicing in any case.

Increase in the Prices of Price-Decontrol Medicines

1607. SHRIMATI SATYA BAHIN :
SHRI H. HANUMANTHAPPA:

Will the PRIME MINISTER be pleased to state :

(a) whether it is a fact that prices of price decontrol medicines have gone up by more than 100 per cent to 200 per cent after the announcement of D.P.C.O. 1987;

(b) whether it is also a fact that his Ministry is monitoring the prices of price-decontrol medicines;

(c) if so, what was the price of Intravel Sodium 500mg vial and 1 gm. vial, Fluothane 250ml, Glycodine 79ml, D.B.I. strip of 10 tabs, Blocin 15mg. per amp Calmpose strip of 10 Tablets, Benedryl Syrup, Deonil Tabs, Dilosyn Expectorant, Berin Injection, Clothalton Tablets before DPCO 1987 and what is the present price of each;

(d) what is the percentage increase in each case and what is the M.A.P.E. taken in each products;